N/A
N=23
Stereotactic Body Radiotherapy for Liver Tumors
Liver Metastases · Hepatocellular Carcinoma · Intrahepatic Cholangiocarcinoma
Bottom Line
View on ClinicalTrials.gov: NCT01347333 ↗Enrolled (actual)
23
Serious AEs
0.0%
Results posted
Mar 2020
Primary outcome: Primary: Local Tumor Recurrence Rate — 4; 0 Participants
Study Design & Population
- Study type
- Interventional
- Phase
- N/A
- Interventions
- Stereotactic body radiosurgery (Radiation); Stereotactic Body Radiotherapy (Radiation)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Mercy Research
- Primary completion
- Sep 2016
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Local Tumor Recurrence Rate |
4; 0 | — |
| SECONDARY Late Complication Rates |
— | — |
Summary
This study will evaluate the local control rate as well as acute and late toxicity rates of stereotactic body radiotherapy for the treatment of liver metastases and unresectable primary liver tumors such as hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Eligibility Criteria
Inclusion Criteria
- Patient age >= 18 years
- Zubrod performance status of 0-3
- Oligometastases (1-3) with aggregate tumor diameter 2.5 g/dL Serum levels of liver enzymes 6 cm
- Prior radiotherapy to the liver
- Pregnant or lactating women, due to potential exposure of the fetus to RT and unknown effects of RT on lactating females
- Patients with psychiatric or addictive disorder that would preclude obtaining informed consent
Data sourced from ClinicalTrials.gov (NCT01347333). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.